✦ LIBER ✦

PCN95 The Cost-Effectiveness of Aprepitant for the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy in Breast Cancer Patients Compared to Current Clinical Practice in Scotland

✍ Scribed by Nikoglou, E.; Humphreys, S.; Pellissier, J.; O' Regan, C.

Book ID: 122785401
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 61 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.1196

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 COST-EFFECTIVENESS ANALYSIS OF APR

PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY

✍ L Annemans; D Strens; E Lox; C Petit; H Malonne 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

9048 Aprepitant for the prevention of ch

9048 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer

✍ Rapoport, B.; Boice, J.A.; Brown, C.; Street, J.C.; Hardwick, J.S.; Carides, A.D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

57LBA Aprepitant (APR) for the preventio

57LBA Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers

✍ R. Gralla; B. Rapoport; C. Brown; J.C. Street; J.S. Hardwick; A.D. Carides 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P104 Aprepitant treated patients were be

P104 Aprepitant treated patients were better able to maintain daily functioning compared to active control therapy after receipt of moderately emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting

✍ A. Molassiotis; T. Wisniewski; A.M. Nguyen; A. Carides 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Palonosetron for prevention of acute and

Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM)

✍ F. Giuliani; G. Cilenti; I. Nugnes; E. Maiello; M. Di Bisceglie; V. Lorusso; V. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 111 KB